Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Nelarabine - eviQ protocol 4510 renal guidance
Product / population
Nelarabine - eviQ protocol 4510 renal guidance; selected source sections, not a full prescribing monograph.
Renal method
Qualitative renal statement; no numeric renal algorithm inferred.
Source revision
eviQ protocol 4510, version 1; reviewed July 22, 2026; initial publication May 7, 2025.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Nelarabine: label evidence gap versus qualitative eviQ guidance
The label cannot recommend a dose below CrCl 50. eviQ describes PK-based no adjustment in mild/moderate impairment but gives no numerical renal bands; scope alignment remains unresolved.
What to reconcile: Obtain oncology/pharmacy adjudication without assigning eviQ an invented cutoff; retain the neurotoxicity stopping rule.
eviQ / Cancer Institute NSW · Nelarabine - eviQ protocol 4510 renal guidance; selected source sections, not a full prescribing monograph.
Renal method: Qualitative renal statement; no numeric renal algorithm inferred. Source date: eviQ protocol 4510, version 1; reviewed July 22, 2026; initial publication May 7, 2025. Retrieved: 2026-09-08
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The eviQ nelarabine protocol says dedicated kidney-dysfunction studies are lacking, but pharmacokinetic analyses support no adjustment for mild to moderate dysfunction. It does not define numeric renal bands in that paragraph. Grade 2 or greater neurotoxicity requires discontinuation. Recommendations are guidance based on limited evidence and require regimen, treatment-intent and patient-specific oncology assessment. This broader qualitative statement does not supply a verified dose below the label's CrCl 50 boundary or a dialysis protocol.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.